FTSE 100 movers: AB Foods and Tullow Oil lead the risers
10th Dec 2012 14:44
Primark and food products giant Associated British Foods was the high riser on the Footsie on Monday afternoon, extending gains after Friday annual general meeting at which it revealed a strong start t o the new financial year. Oil group Tullow Oil was performing well today, rebounding after its re
Read moreBellzone Mining founder sells shares to other stake holder
4th Dec 2012 16:13
The founder of Bellzone Mining, which develops two Iron ore and nickel/copper assets in Guinea, West Africa, has sold 50m shares in the company. Nikolajs Zuks, who has been the company's Managing Director since August 2009, disposed of the shares at 17p each for a total of £8.5m. As a result, Zuk
Read moreLondon close: Losses erased after 'optimistic' fiscal cliff comments
28th Nov 2012 16:43
Comments from US Republican Speaker of the House John Boehner about the 'fiscal cliff' saw the FTSE 100 rally in afternoon trading to finish broadly flat. Markets got off to a poor start this morning after Nevada Democrat Harry Reid said that "little progress" has been made so far on avoiding the f
Read moreFTSE 100 movers: Bunzl falls on reduced price target
28th Nov 2012 14:44
Bunzl shares took a hit after Citigroup cut its target price from 1,250p to 1,190p, and kept a neutral rating. AMEC, Johnson Matthey, National Grid and Tate & Lyle were also registering losses today after going ex-dividend. Medical technology group Smith & Nephew fell after announcing that it is
Read moreLondon midday: 'Fiscal cliff' concerns dampen markets
28th Nov 2012 11:41
- Comments from Harry Reid weigh on sentiment - Intel rumoured to be interested in ARM - Ex-div stocks provide a drag The FTSE 100 was trading firmly in the red on Wednesday, tracking US stocks lower overnight as the market's focus turns from Greece to the US 'fiscal cliff'. The main US equity ben
Read moreBroker tips: Smith & Nephew, Resolution, Compass
28th Nov 2012 11:14
Investec has kept its 'hold' rating and 670p target price for medical technology group Smith & Nephew following Wednesday's proposed acquisition of Healthpoint Biotherapeutics. The broker said that the purchase is a "good fit" but raises the risk profile of the company as a whole. "For us, whilst t
Read moreBroker snap: S&N acquisition increases risk profile, says Investec
28th Nov 2012 11:13
Investec has kept its 'hold' rating and 670p target price for medical technology group Smith & Nephew following Wednesday's proposed acquisition of Healthpoint Biotherapeutics. Healthpoint, which will be acquired for $782m in cash, is a US-based leader in bioactive debridement, dermal repair and re
Read moreLondon open: Stocks fall as focus turns to 'fiscal cliff'
28th Nov 2012 08:31
UK stocks slipped in early trading on Wednesday, tracking US markets lower, as focus turned to the impending US 'fiscal cliff'. "European equities are trading lower this morning being pressured by a late sell-off in the US yesterday evening on fears that so far there has been too little progress be
Read moreLondon pre-open: FTSE set to erase Tuesday's gains
28th Nov 2012 07:26
City sources predict the FTSE 100 will open down 15 points from yesterday's close of 5,800, as concerns over the situation overtakes the confidence which followed the Greek bail-out agreement. The predicted losses will erase all of Tuesday's gains which resulted from the deal. The main US equity
Read moreSmith & Nephew strengthens wound care division with US acquisition - UPDATE
28th Nov 2012 07:06
Medical technology giant Smith & Nephew is to buy the assets of Healthpoint Biotherapeutics in an attempt to bolster its position in advanced wound care. Healthpoint, which will be acquired for $782m in cash, is a US-based leader in bioactive debridement, dermal repair and regeneration wound care t
Read moreSmith & Nephew plucks its new CFO from AstraZeneca
19th Nov 2012 13:24
Global medical technology business Smith & Nephew has appointed a director at AstraZeneca as its new Chief Financial Officer (CFO) to replace Adrian Hennah when he leaves at the end of December. Julie Brown, who has worked for AstraZeneca for 25 years, will formally takeover the role in early Febr
Read moreFTSE 100 movers: Lloyds reports progress and pleases investors
1st Nov 2012 15:32
Banking giant Lloyds rose strongly after an 'in-line' third-quarter statement. The lender said that it is making progress despite delivering a statutory loss before tax of £583m for the first nine months of the year, including a further Payment Protection Insurance (PPI) provision of £1bn in the thi
Read moreSmith & Nephew hobbled by Europe
1st Nov 2012 14:12
Global medical technology business Smith & Nephew experienced hard times in Europe in the third quarter and expects these to continue. Revenue in the three months to September 29th was up an underlying 1% but down an actual 7.8% at $952m from $1,032m the year before. Profit before tax eased to $188
Read moreMonday broker round-up
29th Oct 2012 08:10
African Barrick Gold: HSBC cuts target from 710p to 670p, overweight rating kept. African Eagle Resources: Seymour Pierce keeps buy rating. Anglo American: Nomura cuts target from 2,100p to 2,000p, neutral rating kept; UBS ups target from 2,230p to 2,250p, buy rating kept. Burberry: Goldman Sachs
Read moreWeek ahead: Banking results and election fever to take centre-stage
26th Oct 2012 09:08
Next week is set to be an extremely busy week, looking at the corporate and economic calendar from home and abroad. Third-quarter UK corporate earnings season really gets into full swing with some heavyweight Footsie constituents scheduled to report, including GlaxoSmithKline, Shell, Smith & Nephew
Read more